Comprehensive Diagnostic Work Up In Patients With Suspected Heart Failure And Preserved Ejection Fraction
Source : https://www.sciencedirect.com/science/article/pii/S1109966623001847?via=ihub
Diagnosis of heart failure with preserved ejection fraction (HFpEF) can be challenging and it could require different tests, some of which are affecte...
The aim of this review is to help the clinician in diagnosing HFpEF, overcoming the diagnostic uncertainty, and in disentangling among the different underlying causes, in order to properly treat this kind of patients.
Share
SGLT2 inhibitors: an Evidence-Based Update on cardiovascular Implications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37740906/
The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects...
The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects of SGLT2 inhibitors.
Share
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37670496/
Empagliflozin was found to be the first targeted treatment option that is clinically effective and cost-effective for patients with HF LVEF > 40%. Prescribing empagliflozin with SoC to patients with...
Conclusions: Empagliflozin was found to be the first targeted treatment option that is clinically effective and cost-effective for patients with HF LVEF > 40%. Prescribing empagliflozin with SoC to patients with HF LVEF > 40% is expected to improve clinical outcomes and patients' quality of life and substantially below accepted WTP...
Share
Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37629635/
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of antidiabetic drugs that have shown favorable effects in heart failure (HF) patients, irrespective of the left ventricular ejection fraction (LVEF)....
Conclusions: Dapagliflozin, an SGLT2i, was associated with an improvement in the LV and LA structural and functional echocardiographic markers in patients with HF and DM. In addition, dapagliflozin was associated with a reduction in biomarkers, such as troponin and natriuretic peptides. The abovementioned findings may explain the beneficial...
Share
Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial
Source : https://bmjopen.bmj.com/content/13/8/e070766
Introduction Heart failure (HF) with preserved ejection fraction (HFpEF) has become the main type of HF worldwide. Although large randomised controlled studies have demonstrated the beneficial effects of sodium-glucose cotransporter...
Methods and analysis: This report describes the study design of a prospective, multicentre, randomised, double-blind, placebo-controlled and parallel-group clinical study. A total of 180 participants with HFpEF aged 40–80 years old who meet the inclusion and exclusion criteria will be randomly divided into an empagliflozin treatment group...
Share